The Treatment of Melioidosis
Open Access
- 27 April 2010
- journal article
- review article
- Published by MDPI AG in Pharmaceuticals
- Vol. 3 (5) , 1296-1303
Abstract
Melioidosis is a complex bacterial infection, treatment of which combines the urgency of treating rapidly fatal Gram negative septicaemia with the need for eradication of long-term persistent disease in pulmonary, soft tissue, skeletal and other organ systems. Incremental improvements in treatment have been made as a result of multicentre collaboration across the main endemic region of Southeast Asia and northern Australia. There is an emerging consensus on the three main patterns of antimicrobial chemotherapy; initial (Phase 1) treatment, subsequent eradication (Phase 2) therapy and most recently post-exposure (Phase 0) prophylaxis. The combination of agents used, duration of therapy and need for adjunct modalities depends on the type, severity and antimicrobial susceptibility of infection. New antibiotic and adjunct therapies are at an investigational stage but on currently available data are unlikely to make a significant impact on this potentially fatal infection.Keywords
This publication has 33 references indexed in Scilit:
- In Vitro Activity of Doripenem against Burkholderia pseudomalleiAntimicrobial Agents and Chemotherapy, 2009
- Statins for sepsis: a critical and updated reviewClinical Microbiology and Infection, 2009
- A Simple Scoring System to Differentiate between Relapse and Re-Infection in Patients with Recurrent MelioidosisPLOS Neglected Tropical Diseases, 2008
- Management of Accidental Laboratory Exposure to Burkholderia pseudomallei and B. malleiEmerging Infectious Diseases, 2008
- In vitro activity of ceftobiprole against Burkholderia pseudomalleiJournal of Antimicrobial Chemotherapy, 2007
- A Randomized Controlled Trial of Granulocyte Colony-Stimulating Factor for the Treatment of Severe Sepsis Due to Melioidosis in ThailandClinical Infectious Diseases, 2007
- Risk Factors for Recurrent Melioidosis in Northeast ThailandClinical Infectious Diseases, 2006
- Pharmacokinetic and pharmacodynamic assessment of co-amoxiclav in the treatment of melioidosisJournal of Antimicrobial Chemotherapy, 2006
- Melioidosis: Epidemiology, Pathophysiology, and ManagementClinical Microbiology Reviews, 2005
- Laboratory-Acquired Infection withPseudomonas pseudomallei(Melioidosis)New England Journal of Medicine, 1981